Skip to main content

Table 2 Characteristics of participant country

From: Bedaquiline resistance probability to guide treatment decision making for rifampicin-resistant tuberculosis: insights from a qualitative study

 

Belgium

The Netherlands

The United States

The United Kingdom

Brazil

South Africa

Vietnam

Ethiopia

Number of participants

1

1

1

1

4

4

1

1

Country income level

High

High

High

High

Upper-middle

Upper-middle

Lower-middle

Low

MDR-TB burden

Low

Low

Low

Low

Low

High

High

High

BDQ registration

Registered

Registered

Registered

Registered

Registered

Registered

Registration pending

Registered

National BDQ eligibility guideline

Not publicly available

Patients with RR-TB

Patients \(\ge\) 6 years and weighing \(\ge\) 15 kg with pulmonary MDR-TB

Patients \(\ge\) 6 years with RR-TB

Patients with RR-TB

Patients \(\ge\) 6 years and weighing \(\ge\) 15 kg with RR-TB

Patients \(\ge\) 6 years with RR-TB and without high risk of cardiovascular complication, severe liver disease and severe electrolyte disorder

Patients \(\ge\) 6 years with RR-TB

Conditions for BDQ access

After approval from national TB Consilium

After referral to national reference center

After BDQ order from treating physician is accepted by Metro Medical or Johnson & Johnson Patient Assistance Foundation

After approval from national TB Consilium

As part of operational research (until October 2021)

At all health facilities

Compassionate use after approval from hospital scientific committee

After referral to one of 60 MDR-TB Treatment Initiation Centers

Cost of BDQ (cost for 6 months)

High (~ $22,000)

High (~ $22,000)

High (~ $30,000)

High (~ $22,816)

Low ($340)

Low ($400)

Low ($340)

Low ($340)

Access to WGS for DST

Routine

Routine

Routine

Routine

Research

Research

Research

Research

  1. BDQ Bedaquiline, DST drug susceptibility testing, MDR-TB multi drug-resistant TB, RR-TB rifampicin-resistant TB, WGS whole genome sequencing